BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang S, Huang S, Deng C, Cao Y, Yang J, Chen G, Zhang B, Duan C, Shi J, Kong B, Friess H, Zhao N, Huang C, Huang X, Wang L, Zou X. Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients. Oncotarget 2017;8:18848-60. [PMID: 28061480 DOI: 10.18632/oncotarget.14473] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Ding L, Tian Y, Wang L, Bi M, Teng D, Hong S. Hypermethylated long noncoding RNA MEG3 promotes the progression of gastric cancer. Aging (Albany NY) 2019;11:8139-55. [PMID: 31584879 DOI: 10.18632/aging.102309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Wu S, Jiang J, Liu J, Wang X, Gan Y, Tang Y. Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer. Oncotarget 2017;8:62589-99. [PMID: 28977971 DOI: 10.18632/oncotarget.19880] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
3 Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol 2019;10:38. [PMID: 30761005 DOI: 10.3389/fphar.2019.00038] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 18.0] [Reference Citation Analysis]
4 Sayed AM, Hassanein EH, Salem SH, Hussein OE, Mahmoud AM. Flavonoids-mediated SIRT1 signaling activation in hepatic disorders. Life Sciences 2020;259:118173. [DOI: 10.1016/j.lfs.2020.118173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
5 Lopez-Aguiar AG, Postlewait LM, Ethun CG, Zaidi MY, Zhelnin K, Krasinskas A, Russell MC, Kooby DA, Cardona K, El-Rayes BF, Maithel SK. STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target? J Gastrointest Surg 2020;24:1138-48. [PMID: 31144189 DOI: 10.1007/s11605-019-04261-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Ashrafizadeh M, Zarrabi A, Orouei S, Zarrin V, Rahmani Moghadam E, Zabolian A, Mohammadi S, Hushmandi K, Gharehaghajlou Y, Makvandi P, Najafi M, Mohammadinejad R. STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects. Biology (Basel) 2020;9:E126. [PMID: 32545648 DOI: 10.3390/biology9060126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
7 Li Y, Zhang M, Dorfman RG, Pan Y, Tang D, Xu L, Zhao Z, Zhou Q, Zhou L, Wang Y, Yin Y, Shen S, Kong B, Friess H, Zhao S, Wang L, Zou X. SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism. Neoplasia 2018;20:745-56. [PMID: 29925042 DOI: 10.1016/j.neo.2018.03.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
8 Ye Y, Li J, Jiang D, Li J, Xiao C, Li Y, Han C, Zhao C. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition. Cancer Res Treat 2020;52:1162-77. [PMID: 32599983 DOI: 10.4143/crt.2020.138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Liang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, Liu Y, Duan Y, Chen B, Guo R, Zhao W, Wang L, Yang Q. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis 2018;9:563. [PMID: 29752439 DOI: 10.1038/s41419-018-0582-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
10 Du L, Liu X, Ren Y, Li J, Li P, Jiao Q, Meng P, Wang F, Wang Y, Wang YS, Wang C. Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells. Theranostics 2020;10:9458-76. [PMID: 32863939 DOI: 10.7150/thno.44688] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Skrypek N, Bruneel K, Vandewalle C, De Smedt E, Soen B, Loret N, Taminau J, Goossens S, Vandamme N, Berx G. ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics Chromatin 2018;11:70. [PMID: 30445998 DOI: 10.1186/s13072-018-0239-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zheng P, Wang W, Ji M, Zhu Q, Feng Y, Zhou F, He Q. TMEM119 promotes gastric cancer cell migration and invasion through STAT3 signaling pathway. Onco Targets Ther 2018;11:5835-44. [PMID: 30271166 DOI: 10.2147/OTT.S164045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Liu H, Cheng XH. MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1. Oncotarget 2018;9:12304-15. [PMID: 29552311 DOI: 10.18632/oncotarget.24380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
14 Wang MJ, Chen JJ, Song SH, Su J, Zhao LH, Liu QG, Yang T, Chen Z, Liu C, Fu ZR, Hu YP, Chen F. Inhibition of SIRT1 Limits Self-Renewal and Oncogenesis by Inducing Senescence of Liver Cancer Stem Cells. J Hepatocell Carcinoma 2021;8:685-99. [PMID: 34235106 DOI: 10.2147/JHC.S296234] [Reference Citation Analysis]
15 Calcagno DQ, Wisnieski F, Mota ERDS, Maia de Sousa SB, Costa da Silva JM, Leal MF, Gigek CO, Santos LC, Rasmussen LT, Assumpção PP, Burbano RR, Smith MA. Role of histone acetylation in gastric cancer: implications of dietetic compounds and clinical perspectives. Epigenomics 2019;11:349-62. [DOI: 10.2217/epi-2018-0081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ghaedi H, Mozaffari MAN, Salehi Z, Ghasemi H, Zadian SS, Alipoor S, Hadianpour S, Alipoor B. Co-expression profiling of plasma miRNAs and long noncoding RNAs in gastric cancer patients. Gene 2019;687:135-42. [PMID: 30447342 DOI: 10.1016/j.gene.2018.11.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
17 Ding K, Tan S, Huang X, Wang X, Li X, Fan R, Zhu Y, Lobie PE, Wang W, Wu Z. GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis. J Biol Chem 2018;293:3949-64. [PMID: 29367342 DOI: 10.1074/jbc.RA117.001103] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
18 Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel JC. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α. Melanoma Res 2018;28:204-10. [PMID: 29485532 DOI: 10.1097/CMR.0000000000000435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
19 Sun M, Du M, Zhang W, Xiong S, Gong X, Lei P, Zha J, Zhu H, Li H, Huang D, Gu X. Survival and Clinicopathological Significance of SIRT1 Expression in Cancers: A Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:121. [PMID: 30930849 DOI: 10.3389/fendo.2019.00121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Zhao B, Li X, Zhou L, Wang Y, Shang P. SIRT1: a potential tumour biomarker and therapeutic target. J Drug Target 2019;27:1046-52. [PMID: 31056963 DOI: 10.1080/1061186X.2019.1605519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Xu Y, Lai Y, Weng H, Tan L, Li Y, Chen G, Luo X, Ye Y. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway. Aging (Albany NY) 2019;11:2551-64. [PMID: 31056532 DOI: 10.18632/aging.101876] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
22 Zhou S, Zhang S, Wang L, Huang S, Yuan Y, Yang J, Wang H, Li X, Wang P, Zhou L, Yang J, Xu Y, Gao H, Zhang Y, Lv Y, Zou X. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling. Oncogenesis 2020;9:33. [PMID: 32157097 DOI: 10.1038/s41389-020-0218-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
23 Özcan Ö, Belli AK, Sakallı Çetin E, Kara M, Çelik Öİ, Kaplan M, Kayılıoğlu SI, Dönmez C, Polat M. Upregulation of SIRT1 gene in gastric adenocarcinoma. Turk J Gastroenterol 2019;30:326-30. [PMID: 30945643 DOI: 10.5152/tjg.2019.18550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Zhang S, Yang Y, Huang S, Deng C, Zhou S, Yang J, Cao Y, Xu L, Yuan Y, Yang J, Chen G, Zhou L, Lv Y, Wang L, Zou X. SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP‐13 signaling. J Cell Physiol 2019;234:15395-406. [DOI: 10.1002/jcp.28186] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
25 Xiang R, Han X, Ding K, Wu Z. CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells. Pathol Res Pract 2020;216:152776. [PMID: 31822364 DOI: 10.1016/j.prp.2019.152776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]